Arterial Stiffness Test Beats Standard Score for Heart Risk in Autoimmune Disease
A simple ultrasound test predicted cardiovascular events far better than SCORE2 in rheumatic disease patients, offering a new screening tool.
Summary
People with autoimmune rheumatic diseases like rheumatoid arthritis face 50–100% higher cardiovascular risk than the general population, yet standard risk calculators often miss it. A new study followed 143 patients for seven years and found that carotid-femoral pulse wave velocity (cfPWV) — a quick, non-invasive ultrasound measure of arterial stiffness — predicted heart attacks, strokes, and other cardiovascular events with an accuracy score of 0.84, compared to just 0.56 for the widely used SCORE2 system. That near-coin-flip score for SCORE2 highlights a real gap in care. Arterial stiffness, which standard risk tools ignore, appears to capture the excess cardiovascular danger driven by chronic inflammation in rheumatic conditions. This test could meaningfully improve how rheumatologists identify high-risk patients early.
Detailed Summary
For patients living with autoimmune rheumatic diseases like rheumatoid arthritis, systemic sclerosis, or spondyloarthritis, the cardiovascular system faces a silent and persistent threat. Chronic inflammation accelerates arterial aging and roughly doubles the risk of heart attack, stroke, and related events compared to the general population. Yet the tools doctors typically use to estimate that risk were not built with these patients in mind.
A new study published in RMD Open followed 143 patients with these three conditions over a median of seven years, tracking 20 cardiovascular events. Researchers compared the predictive accuracy of carotid-femoral pulse wave velocity (cfPWV) — an ultrasound-based measure of how stiff the arteries have become — against SCORE2, the standard European cardiovascular risk calculator.
The results were striking. cfPWV achieved an area under the curve of 0.84, meaning it correctly distinguished future event patients from non-event patients with strong accuracy. SCORE2 scored just 0.56 — barely better than random chance. Sensitivity for cfPWV was 87% versus 60% for SCORE2, meaning far fewer high-risk patients would be missed using the newer approach.
Why does this matter? Arterial stiffness is a direct downstream consequence of inflammation-driven vascular damage — precisely the mechanism that elevates cardiovascular risk in rheumatic disease. SCORE2 relies on conventional factors like age, cholesterol, and blood pressure, which do not capture this inflammatory burden. cfPWV essentially reads the biological damage already done to vessel walls.
Practically, cfPWV is non-invasive, relatively quick, and deliverable in a clinical setting. If validated in larger studies, it could become a routine screening tool in rheumatology clinics. The study's limitations include a small sample size and reliance on self-reported follow-up events, so replication in larger, prospective cohorts is needed before clinical guidelines shift.
Key Findings
- cfPWV predicted cardiovascular events with AUC of 0.84 vs 0.56 for SCORE2 in rheumatic disease patients
- cfPWV sensitivity was 87% vs 60% for SCORE2, catching far more true high-risk patients
- Arterial stiffness captures inflammation-driven vascular damage that standard risk calculators miss
- Rheumatic disease patients face 50–100% higher cardiovascular risk than comparable healthy adults
- The test is non-invasive and ultrasound-based, making it feasible for routine rheumatology practice
Methodology
This is a news report summarizing a peer-reviewed study published in RMD Open, a credible rheumatology journal. The study was a retrospective observational cohort of 143 patients followed for a median of seven years, with 20 cardiovascular events recorded. Follow-up data were collected via patient self-report by phone, which introduces recall bias.
Study Limitations
The study was modestly powered with only 143 patients and 20 events, limiting statistical confidence. Cardiovascular event data were self-reported via telephone follow-up, introducing potential recall and reporting bias. Larger prospective trials with objective event adjudication are needed before cfPWV replaces or formally supplements current risk stratification guidelines.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.